Asset Details
Do you wish to reserve the book?
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Do you wish to request the book?
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
2023
Overview
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, magement, and specific treatment. The availability of new disease-modifying therapies has made successful treatment a reality. Transthyretin amyloid cardiomyopathy can be either age-related (wild-type form) or caused by mutations in the TTR gene (genetic, hereditary forms). It is a systemic disease, and while the genetic forms may exhibit a variety of symptoms, a predomint cardiac phenotype is often present.This document aims to provide an overview of ATTR-CM amyloidosis focusing on cardiac involvement, which is the most critical factor for prognosis. It will discuss the available tools for early diagnosis and patient magement, given that specific treatments are more effective in the early stages of the disease, and will highlight the importance of a multidiscipliry approach and of specialized amyloidosis centres.To accomplish these goals, the World Heart Federation assembled a panel of 18 expert clinicians specialized in TTR amyloidosis from 13 countries, along with a representative from the Amyloidosis Alliance, a patient advocacy group.This document is based on a review of published literature, expert opinions, registries data, patients’ perspectives, treatment options, and ongoing developments, as well as the progress made possible via the existence of centres of excellence.From the patients’ perspective, increasing disease awareness is crucial to achieving an early and accurate diagnosis. Patients also seek to receive care at specialized amyloidosis centres and be fully informed about their treatment and prognosis.
Publisher
Ubiquity Press
Subject
